AWARD NUMBER: W81XWH-13-1-0470

TITLE:
Identification and Targeting of Candidate Preexisting Lurker Cells That Give Rise to Castration-Resistant Prostate Cancer

PRINCIPAL INVESTIGATOR: Andrew Goldstein

CONTRACTING ORGANIZATION:
University of California, Los Angeles
Los Angeles, CA 90095-1406

REPORT DATE:
October 2016

TYPE OF REPORT: Annual Report

PREPARED FOR:
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Identification and Targeting of Candidate Pre-Existing Lurker Cells that Give Rise to Castration-Resistant Prostate Cancer

Goldstein, Andrew
E-Mail: AGoldstein@mednet.ucla.edu

University of California, Los Angeles
11000 Kinross Avenue, Suite 211
Los Angeles, CA 90095-1406

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

Approved for public release; distribution unlimited

Castration-resistant prostate cancer (CRPC) is a lethal disease. We lack standard biomarkers to predict hormonal sensitivity of tumors, and we need new targets for therapy to prevent or treat CRPC. The selection theory predicts that pre-existing androgen-independent prostate cancer cells (termed lurker cells) contribute to CRPC, as they are not targeted by androgen deprivation therapy and may be capable of regenerating the tumor. Therefore, targeting these predicted lurker cells in combination with androgen-deprivation therapy would likely prevent or delay the onset of CRPC. The goals of this proposal are to provide functional evidence for intermediate luminal progenitor cells as the pre-existing “lurker” cells in primary prostate tumors, to evaluate potential therapeutic targets in intermediate luminal progenitor cells, and to define candidate biomarkers in intermediate luminal progenitor cells that can predict prognosis and response to hormonal therapy.

Prostate, epithelial, Androgen-deprivation therapy, Castration-resistant prostate cancer, luminal progenitor, intermediate cell, lurker cell
### TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. INTRODUCTION</td>
<td>2</td>
</tr>
<tr>
<td>2. KEYWORDS</td>
<td>2</td>
</tr>
<tr>
<td>3. ACCOMPLISHMENTS</td>
<td>2</td>
</tr>
<tr>
<td>4. IMPACT</td>
<td>6</td>
</tr>
<tr>
<td>5. CHANGES/PROBLEMS</td>
<td>6</td>
</tr>
<tr>
<td>6. PRODUCTS</td>
<td>7</td>
</tr>
<tr>
<td>7. PARTICIPANTS &amp; OTHER COLLABORATING ORGANIZATIONS</td>
<td>8</td>
</tr>
<tr>
<td>8. SPECIAL REPORTING REQUIREMENTS</td>
<td>9</td>
</tr>
<tr>
<td>9. APPENDICES</td>
<td>9</td>
</tr>
</tbody>
</table>
1. INTRODUCTION
Castration-resistant prostate cancer (CRPC) is a lethal disease. We lack standard biomarkers to predict hormonal sensitivity of tumors, and we need new targets for therapy to prevent or treat CRPC. The adaptation theory predicts that pre-existing androgen-independent prostate cancer cells (termed lurker cells) contribute to CRPC, as they are not targeted by androgen-deprivation therapy and may be capable of regenerating the tumor. Therefore, targeting these predicted lurker cells in combination with androgen-deprivation therapy would likely prevent or delay the onset of CRPC. The goals of this proposal are to provide functional evidence for intermediate luminal progenitor cells as the pre-existing “lurker” cells in primary prostate tumors, to evaluate potential therapeutic targets in intermediate luminal progenitor cells, and to define candidate biomarkers in intermediate luminal progenitor cells that can predict prognosis and response to hormonal therapy.

2. KEYWORDS
Prostate, epithelial, Androgen-deprivation therapy, Castration-resistant prostate cancer, luminal progenitor, intermediate cell, lurker cell, CD38, inflammation

3. ACCOMPLISHMENTS
What were the major goals of the project?
Specific Aim 1. Interrogation of human I/LP cells as candidate lurker cells. Time frame: months 1-24. This aim is complete.
Task 1. Test the in vivo effects of castration on human luminal cancer subsets isolated from primary regenerated prostate tumors.
Task 2. Test the in vivo growth capacity of human luminal cancer subsets isolated from primary clinical prostate tumors.
Task 3. Test the in vivo effects of castration on human luminal cancer subsets isolated from primary clinical prostate tumors.

Specific Aim 2. Proof of principle therapeutic targeting of I/LP cells to prevent CRPC. Time frame: months 1-36. This aim is complete.
Task 4. Determine if I/LP cancer cells from primary clinical human prostate tumors express genes associated with CRPC.
Task 6. Target I/LP cells in vivo.

Specific Aim 3. Diagnostic potential of I/LP cells as lurker cells to predict CRPC development. Time frame: months 1-36. This aim is 66% complete as Task 7 and 8 are accomplished while 9 will be performed in the remaining year covered by the no-cost extension.
Task 7. Determine whether I/LP cell transcriptional signature can predict patient prognosis.
Task 8. Testing of candidate I/LP biomarkers on prostate cancer tissue.
Task 9. Determine if I/LP biomarkers can predict hormone sensitivity.

What was accomplished under these goals?
Specific Aim 1. Interrogation of human I/LP cells as candidate lurker cells.

1) major activities: We analyzed expression of the biomarker that distinguishes progenitor cells (CD38-lo) from non-progenitor cells (CD38+) on prostate tissues from patients who would be considered intact compared to castrated, based on treatment with anti-androgen therapies.

2) specific objectives: (1) Test the in vivo effects of castration on human luminal cancer subsets isolated from primary regenerated prostate tumors, (2) Test the in vivo growth capacity of human luminal cancer subsets isolated from primary clinical prostate tumors, (3) Test the in vivo effects of castration on human luminal cancer subsets isolated from primary clinical prostate tumors

3) significant results or key outcomes: In benign human prostate tissues from 6 patients undergoing radical prostatectomy, an average of 38% of luminal cells were CD38-low. In contrast, an average of 89% of luminal cells were CD38-low in benign glands adjacent to cancer from 7 patients treated with anti-androgen therapy (including Bicalutamide and Lupron) for a range of 5 months up to 20 years prior to biopsy or radical prostatectomy (Fig. 1). These results indicate that CD38-lo cells are preferentially castration-resistant.

4) other achievements: Nothing to report

Specific Aim 2. Proof of principle therapeutic targeting of I/LP cells to prevent CRPC.

1) major activities: We identified CD74 as a candidate target expressed in CD38-lo cells and evaluated the role of CD38 in cell proliferation.
2) specific objectives: (1) Determine if I/LP cancer cells from primary clinical human prostate tumors express genes associated with CRPC. (2) Determine regulators of I/LP clonogenic activity in vitro. (3) Target I/LP cells in vivo.

3) significant results or key outcomes: We determined that CD74 expression is inversely correlated with AR activity and PSA expression (Figure 2). CD74 is uniquely expressed in AR-negative, PSA-negative prostate cancer cells (Figure 3), further supporting an association with castration-resistance. We found that CD74 expression can be detected in a subset of tumor tissues prior to castration (Figure 4), suggesting that these tumors may preferentially resist castration.

4) other achievements: We over-expressed CD38 in a variety of cell-types and found a negative impact on growth, suggesting that CD38 restricts the progenitor activity of prostate cells.

Specific Aim 3. Diagnostic potential of I/LP cells as lurker cells to predict CRPC development.
1) major activities: We performed immunohistochemical staining for CD38, a marker that distinguishes progenitor (CD38-low) from non-progenitor (CD38-high) epithelial cells, in tissue microarrays containing normal, PIN, low grade and high grade prostate cancer and used statistical analysis to identify correlations. We also performed statistical analysis using mRNA expression of CD38 to determine its association with outcome.

2) specific objectives: (1) Determine whether I/LP cell transcriptional signature can predict patient prognosis. (2) Testing of candidate I/LP biomarkers on prostate cancer tissue. (3) Determine if I/LP biomarkers can predict hormone sensitivity.

3) significant results or key outcomes: We have found that CD38 protein expression is inversely correlated with disease progression (Figure 5, a and b) and that low expression of CD38 mRNA in radical prostatectomy tissues is prognostic for biochemical recurrence and metastasis (Figure 5, c-e).

Fig. 5. Association of CD38-low phenotype with prostate cancer progression. (A) Plot of composite CD38 staining score in tissues histologically classified as normal, Prostate intraepithelial neoplasia (PIN), or prostate cancer (CA) with Gleason scores less than 7, or 7-10. Middle bar represents mean value. The overall effect of different levels of CD38 among the prostate regions was confirmed (p<0.001). (B) Representative images of normal, PIN, Gleason 6 and Gleason 8 cancer stained for CD38 with high power images below. Scale bars, 50 microns. (C-D) Survival analysis from MSKCC cohort measuring biochemical recurrence and metastasis for tumors containing CD38 mRNA 1 standard deviation below the mean compared to the remainder (non-CD38-low). Log rank (Mantel Cox) p<0.001 (recurrence) and p=0.002 (metastasis). (E) Survival analysis from TCGA cohort measuring biochemical recurrence comparing CD38 expression less than (CD38-low) or greater than (Non-CD38-low) the mean z-score. Log rank (Mantel Cox) p = 0.001.
4) other achievements: We also found that CD38 protein expression in benign glands is inversely correlated with biochemical recurrence in a statistically significant manner, a result we will confirm on a second cohort using the benign tissues in the PSA progression TMA.

What opportunities for training and professional development has the project provided? The Principal Investigator was invited to participate in the Prostate Cancer Foundation’s Coffey-Holden Prostate Cancer Academy in June 2016 and present work at the UCLA SPORE in Prostate Cancer Annual Symposium and the DOD PCRP IMPACT meeting in August 2016.

How were the results disseminated to communities of interest? Major findings were reported in a publication in Cell Reports in addition to press releases by UCLA’s Jonsson Comprehensive Cancer Center and a video on youtube: https://www.youtube.com/watch?v=2zcei5_af5M

What do you plan to do during the next reporting period to accomplish the goals? We plan to further investigate the ability of CD38 expression to predict hormone sensitivity. We will perform staining and statistical analysis on the PSA progression TMA set from the Prostate Cancer Biorepository Network. We will also characterize cells over-expressing CD38 to determine if they exhibit gene expression changes associated with cell cycle inhibition.

4. IMPACT

What was the impact on the development of the principal discipline(s) of the project? Our focus has turned to the role of CD38 as a biomarker and a negative regulator of progenitor activity in the prostate. The recent publication highlights a role for inflammation in the expansion of progenitor cells that are precursors for prostate cancer.

What was the impact on other disciplines? Nothing to Report

What was the impact on technology transfer? Nothing to Report

What was the impact on society beyond science and technology? Nothing to Report

5. CHANGES/PROBLEMS

Changes in approach and reasons for change
Actual or anticipated problems or delays and actions or plans to resolve them
During the first two years of the grant, we carefully evaluated the role of CD38-low progenitor-like cells in prostate cancer and identified critical pathways important for the growth of CD38-low progenitor-like cells which are not reliant on androgen signaling for their survival. We made progress investigating the potential for CD38 expression to be used as a biomarker but immunohistochemical studies aimed to further explore its utility in large cohorts were interrupted by the laboratory move. The additional time in our no-cost extension will enable us to establish our immunohistochemical protocols in the new facility and complete the proposed studies.

Changes that had a significant impact on expenditures
Out of $225,000 budgeted for this grant proposal, we have $13,255.08 unused funds. The main reasons for this balance are that (1) the SRAI Xian Liu left UCLA to pursue work in industry, and (2) the P.I. Goldstein became an Assistant Professor which included packing up, moving and unpacking the laboratory, hiring new employees and transitioning to a new academic department, all of which delayed the remaining experiments related to biomarker development as detailed in the proposal. The remaining budget will be used on laboratory supplies for immunohistochemical reagents, slides/shipping costs from the Prostate Cancer Biorepository Network, and costs for scanning tissue microarrays. Andrew Goldstein, Ph.D. (Assistant Professor, salary covered in full by the Department of Urology) will supervise the experiments. Dr. Takao Hashimoto, Ph.D. (Staff Research Associate III) will perform experiments originally planned to be performed by Xian Liu. Dr. Hashimoto has many years of experience performing immunohistochemical analysis of human tissues and has been trained in Dr. Goldstein’s laboratory.

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents
Nothing to Report

Significant changes in use or care of human subjects
Nothing to Report

Significant changes in use or care of vertebrate animals
Nothing to Report

Significant changes in use of biohazards and/or select agents
Nothing to Report

6. PRODUCTS

Publications, conference papers, and presentations
Work describing the role of luminal progenitor-like cells in prostate cancer and the CD38 biomarker were reported in a 2016 Cell Reports paper. Data was also presented at a 2016 Prostate Cancer Foundation conference in San Diego, CA and the 2016 DOD PCRP IMPACT meeting in Baltimore, MD.

**Journal publications**


**Books or other non-periodical, one-time publications**

Nothing to Report

**Other publications, conference papers, and presentations**

The Principal Investigator Andrew Goldstein presented his work “CD38 links stem/progenitor cells and metabolism in prostate cancer” at the UCLA SPORE in Prostate Cancer Annual Symposium in September, 2016 and “Progenitor cells, cancer and metabolism in prostate epithelium” at the UCLA Cell and Developmental Biology Club in October, 2016.

**Website(s) or other Internet site(s)**

Nothing to Report

**Technologies or techniques**

Nothing to Report

**Inventions, patent applications, and/or licenses**

Nothing to Report

**Other Products**

Nothing to Report

---

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?
Name: Andrew Goldstein  
Project Role: PI  
Nearest Person Month Worked: 3  
Contribution to Project: Supervision of the project, immunohistochemical analysis, in vitro/in vivo growth assays.

Name: Xian Liu  
Project Role: Technician/Staff Research Associate  
Nearest Person Month Worked: 6  
Contribution to Project: Performed immunohistochemical staining, lentiviral transduction, in vitro and in vivo growth assays.

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?  
Yes, the PI has acquired new funding.

What other organizations were involved as partners?  
Nothing to Report

8. SPECIAL REPORTING REQUIREMENTS
N/A

9. APPENDICES
See attached 2016 Cell Reports article
Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome

Highlights

- Low expression of CD38 enriches for luminal progenitor cells in human prostate
- CD38lo luminal cells are localized in proximity to prostatic inflammation
- CD38lo luminal cells are target cells for aggressive human prostate cancer
- Low CD38 in prostate cancer is prognostic for biochemical recurrence and metastasis

In Brief

Chronic inflammation of the prostate is a risk factor for cancer, but how inflammation increases disease risk remains poorly defined. Liu et al. show that luminal progenitor cells expressing low levels of CD38 are expanded around inflammation, and these progenitors are target cells that can initiate human prostate cancer.

Accession Numbers

GSE89050

Authors

Xian Liu, Tristan R. Grogan, Haley Hieronymus, ..., Jiaoti Huang, Owen N. Witte, Andrew S. Goldstein

Correspondence

agoldstein@mednet.ucla.edu
Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome

Xian Liu,1 Tristan R. Grogan,3 Haley Hieronymus,1 Takao Hashimoto,1 Donghui Cheng,5 Lijun Zhang,2 Kevin Huang,3 Tanya Stoyanova,6,12 Jung Wook Park,6 Ruzanna O. Shkhyan,1 Behdokht Nowroozizadeh,1 Matthew B. Rettig,5,6,11 Charles L. Sawyer,4 David Elashoff,3,11 Steve Horvath,12,13 Jiaoti Huang,5,7,11,16 Owen N. Witte,2,5,6,11,14 and Andrew S. Goldstein1,5,10,11,17,*

1Molecular, Cell and Developmental Biology, University of California, Los Angeles, Los Angeles, CA 90095, USA
2Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
3Department of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
4Programs in Human Oncology and Pathogenesis, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
5Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA
6Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA
7Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
8Division of Hematology-Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
9VA Greater Los Angeles Healthcare System, Los Angeles, CA 90024, USA
10Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
11Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA
12Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
13Biostatistics, UCLA Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA 90095, USA
14Howard Hughes Medical Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA
15Present address: Department of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University School of Medicine, Palo Alto, CA 94304, USA
16Present address: Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA
17Lead Contact
*Correspondence: agoldstein@mednet.ucla.edu

http://dx.doi.org/10.1016/j.celrep.2016.11.010

SUMMARY

Inflammation is a risk factor for prostate cancer, but the mechanisms by which inflammation increases that risk are poorly understood. Here, we demonstrate that low expression of CD38 identifies a progenitor-like subset of luminal cells in the human prostate. CD38lo luminal cells are enriched in glands adjacent to inflammatory cells and exhibit epithelial nuclear factor κB (NF-κB) signaling. In response to oncogenic transformation, CD38lo luminal cells can initiate human prostate cancer in an in vivo tissue-regeneration assay. Finally, the CD38lo luminal phenotype and gene signature are associated with disease progression and poor outcome in prostate cancer. Our results suggest that prostate inflammation expands the pool of progenitor-like target cells susceptible to tumorigenesis.

INTRODUCTION

An inflammatory microenvironment is a critical component driving tumorigenesis, from cancer initiation to metastasis to end-stage treatment-resistant lethal disease (Das Roy et al., 2009; Gurel et al., 2014; Liu et al., 2013; Wang et al., 2015). In many adult tissues, cancers originate in sites of chronic inflammation (Coussens and Werb, 2002). It is hypothesized that sustained proliferative signals from inflammatory cells can cooperate with oncogenic events to promote tumorigenesis (De Marzo et al., 2007). Mouse models have been developed that recapitulate features of inflammation in the tumor microenvironment and demonstrate a role for defined immune cell types and inflammatory cytokines in cancer initiation and progression (Ammirante et al., 2010; Garcia et al., 2014). Few studies have investigated the functional consequences of inflammation in human epithelial tissues.

Chronic inflammation of the prostate is a risk factor for aggressive prostate cancer (Gurel et al., 2014; Sfanos and De Marzo, 2012; Shafique et al., 2012), as men with chronic inflammation in benign tissues have greater than double the risk for developing high-grade disease compared to men with no inflammation in their benign biopsy cores (Gurel et al., 2014). Groundbreaking work from De Marzo and colleagues has defined a series of histological changes associated with chronic inflammation in the human prostate known as proliferative inflammatory atrophy (PIA) as a likely precursor for prostate cancer (De Marzo et al., 1999, 2007). In PIA, the luminal epithelial layer in close proximity to infiltrating immune cells is...
described as having an atrophic appearance with an increased proliferative index, suggesting a regenerative response (De Marzo et al., 2003). Luminal cells associated with PIA exhibit reduced androgen signaling and increased expression of the anti-apoptotic factor BCL2 (De Marzo et al., 1999, 2003). PIA cells are thought to exhibit an intermediate state of differentiation between basal and luminal cells and are predicted to serve as target cells in prostate tumorigenesis (van Leenders et al., 2003). Several groups have modeled inflammation in the mouse prostate using a variety of approaches, including bacterial infection (Elkahwaji et al., 2009; Khalili et al., 2010; Kwon et al., 2014), high-fat diet (Kwon et al., 2016), and adoptive transfer of prostate-targeting T cells (Haverkamp et al., 2011), demonstrating that prostatic inflammation is associated with increased epithelial proliferation. However, mouse models may not recapitulate the complex environment of aged human prostate tissues exposed to chronic inflammation for years prior to the development of prostate cancer (Gurel et al., 2014).

Lineage tracing in the mouse has demonstrated that both basal and luminal cells are sufficient to initiate prostate cancer following Pten deletion, with differences in tumor outcome depending on the genetic background and status of Nkx3-1 (Choi et al., 2012; Lu et al., 2013; Wang et al., 2013). Luminal cells can initiate murine prostate cancer in diverse genetically engineered mouse models (Wang et al., 2014), while purified basal cells can respond to a range of oncogene combinations to generate murine tumors using a tissue-regeneration approach (Lawson et al., 2010). In the human prostate, we and others have demonstrated that basal cells isolated from benign human prostate can give rise to tumors following oncogenic transformation (Goldstein et al., 2008; Stoyanova et al., 2013). To date, luminal cells in the human prostate have only been shown to initiate indolent-like tumors with limited proliferation (Park et al., 2016), perhaps due to the low rate of proliferation among luminal cells (De Marzo et al., 1999). In contrast, luminal cell proliferation is increased in regions associated with inflammation in human prostate (De Marzo et al., 1999), suggesting that luminal cells isolated from regions with inflammation may exhibit progenitor cell features and give rise to aggressive prostate cancer.

Here, we report that expression of the luminal cell marker CD38 is heterogeneous in the human prostate. We used low expression of CD38 to isolate a subset of p63-negative, keratin 14 (K14)-negative, keratin 18 (K18)-positive luminal cells from primary benign human prostate with unique functional and molecular properties compared to CD38hi luminal cells. Human prostate CD38lo CD38hi luminal cells are expanded in regions with inflammation, express markers of PIA, and are enriched for progenitor activity. In human tissues, CD38 is inversely correlated with prostate cancer progression and low CD38 mRNA in tumors is prognostic for biochemical recurrence and metastasis. Finally, CD38lo luminal cells can initiate prostate cancer in response to oncogenic transformation using a human tissue regeneration model in immune-deficient mice. These collective results support inflammation-associated luminal cells as a target cell for aggressive prostate cancer.

**RESULTS**

**Differential Expression of CD38 Enables Isolation of Two Distinct Luminal Subsets**

CD38 is reported as a marker of luminal cells in the human prostate (Kramer et al., 1999), and gene expression studies demonstrate that CD38 mRNA can distinguish basal from luminal cells (Smith et al., 2015). We measured cell-surface expression of CD38 by flow cytometry and confirmed that within the EpCAM+ CD45− epithelial fraction, CD38 is expressed by CD26hi luminal cells, but not by CD49f-hi basal cells (Figure 1A). Upon performing immunohistochemical staining for CD38 in human prostate tissue, we noted heterogeneous staining within the luminal layer, including areas where CD38 expression was reduced within individual glands (Figure 1B).

We set out to viably isolate luminal cells based on variations in surface expression of CD38 using fluorescence-activated cell sorting (FACS). After removing CD45+ immune cells and gating on EpCAM+ epithelial cells, we observed three cell populations based on expression of CD49f and CD38 (Figure 1C) in preparations of dissociated cells isolated from benign human prostate tissue. Intracellular flow cytometry revealed that both CD49f-lo CD38hi and CD49fhi CD38lo subsets expressed high levels of the luminal marker K18 (Figures 1D and S1A). Western blot analysis demonstrated that basal markers p63 and K14 are not expressed in either luminal subset (Figure 1E). We noted elevated expression of keratin 5 (K5), a marker of a proposed intermediate-type luminal cell (van Leenders et al., 2003), in CD38lo compared to CD38hi luminal cells (Figure S1B). Following cell isolation, cell diameters were measured to examine differences in size among the three epithelial populations. CD38lo luminal cells demonstrated an average diameter intermediate between basal and CD38hi luminal cells (Figure 1F). These findings indicate that CD38 stratifies luminal cells into two distinct subpopulations. Importantly, CD38hi luminal cells do not express CD26 by flow cytometry (Figure S1C). These data indicate that CD38lo luminal cells are distinct from CD26hi luminal cells and represent a population not previously investigated in prior studies (Karthaus et al., 2014; Park et al., 2016; Stoyanova et al., 2013).

**CD38lo Luminal Cells Are Enriched for Progenitor Activity Compared to CD38hi Luminal Cells**

In order to test the functional capacity of distinct luminal subsets, it is important to remove any potential contaminating basal cells that are highly clonogenic in progenitor assays (Goldstein et al., 2008; Karthaus et al., 2014; Park et al., 2016). We used a double-sorting approach to isolate highly purified preparations of CD38lo and CD38hi luminal cells from benign human prostate tissue and confirmed an absence of basal cells based on lack of expression of CD49f (Figure 2A) and p63 (Figures S2A and S2B). In a two-dimensional colony-forming assay and a three-dimensional sphere-forming assay (Lawson et al., 2010; Lukacs et al., 2010), CD38lo luminal cells exhibited progenitor activity intermediate between the highly clonogenic basal cells and the CD38hi luminal cells (Figures 2B and 2C). In a culture system adapted for the growth of human prostate-like tissue in vitro (Karthaus et al., 2014), CD38lo luminal cells were highly (4- to 5-fold) enriched for organoid formation compared to CD38hi luminal cells.
CD38lo luminal cell-derived organoids contained cells expressing both basal (K5 and p63) and luminal (K8) markers (Figures 2E and S2C), similar to what has been reported for CD26+ luminal cells (Karthaus et al., 2014). When double-sorted cells were plated at single-cell density and visually confirmed, 5% (9/177) of single CD38lo luminal cells were capable of generating organoids (Figure 2F), which is considerably greater than the rate of CD38hi luminal cells (1/142) and the 1% rate reported for CD26+ luminal cells (Karthaus et al., 2014; Park et al., 2016).

CD38lo Luminal Cells Exhibit an Inflammatory Signature

To investigate potential mechanisms regulating differential progenitor activity, we performed RNA sequencing (RNA-seq) and microarray analysis. We generated an RNA-seq signature comprised of 449 genes greater than 2 fold-enriched in CD38lo luminal cells compared to CD38hi luminal cells (Figure 3A). A number of inflammatory-related genes including cytokines (Tnf, Il6, and Il8) and chemokines (Cxcl1, Cxcl2, Cxcl3, Cxcl6, Ccl2, and Ccl20) are enriched in CD38lo luminal cells (Figure 3A). We performed pathway analysis using DAVID Bioinformatics (Huang da et al., 2009) and found the most significant keywords included “inflammatory signaling” and “immune response” (Figure 3B). The significant pathways and inflammatory-related genes were confirmed to be upregulated in CD38lo luminal cells by microarray analysis. We confirmed activation of the nuclear factor kappa B (NF-κB) pathway at the protein level based on phosphorylated p65 and expression of BCL2 by western blot (Figure 3C). In tissue sections, we found that phosphorylated p65 was highly expressed in CD38lo luminal cells in a pattern inversely correlated with CD38 (Figure 3D). Ingenuity pathway analysis identified tumor necrosis factor alpha (TNF) as a likely upstream regulator of CD38lo luminal cells. We confirmed that TNF is expressed in CD38lo cells but absent from CD38hi luminal cells by immunohistochemistry (Figure S3A), suggesting that TNF may activate NFkB signaling in CD38lo cells. We observed a diminution of p65 phosphorylation and reduced expression of BCL2 in...
CD38\textsuperscript{lo} cells following treatment with the NF-\textkappaB pathway inhibitor ACHP (Figure S3B). In a functional assay, ACHP treatment blocked the organoid-forming progenitor activity of CD38\textsuperscript{lo} luminal cells to a greater extent than other epithelial subsets (Figure S3C).

\textbf{CD38\textsuperscript{lo} Luminal Cells Are Expanded in Glands Adjacent to Inflammation}

Based on their gene expression profiling, including genes associated with PIA and inflammation, we investigated expression of CD38 in regions containing inflammatory infiltration (Figure 3E). Staining for CD38 and CD45 on serial slides indicates that CD38 expression is reduced adjacent to CD45\textsuperscript{+} cells (Figure 3F). We stained for a panel of immune cell subsets and found evidence of CD4\textsuperscript{+} and CD8\textsuperscript{+} T cells, CD11c\textsuperscript{+} and CD68\textsuperscript{+} myeloid cells, and CD20\textsuperscript{+} B cells adjacent to regions of the gland with low expression of CD38 (Figure S3D). In order to better define the relationship between CD38 expression and inflammation, we stratified glands into three categories: normal, inflamed, and atrophic, as classified by an expert pathologist. Inflamed glands were identified by pathologic criteria and confirmed with CD38 staining. Atrophic glands were identified by pathologic criteria and generally measured less than 20 \mu m from the basement membrane to the lumen in contrast to normal glands (Figure S3E). Loss of CD38 expression was measured in 95\% (38/40) of inflamed glands, 88\% (35/40) of atrophic glands, and only 10\% (4/40) of normal glands from representative patient samples. Similar results were obtained for TNF, with strong expression in inflamed (38/40) and atrophic glands (33/40) with rare expression in normal glands (1/40). We further explored the connection between immune cells and CD38\textsuperscript{lo} luminal cells by flow cytometry in benign human prostate tissues from 29 distinct patient samples. We found a statistically significant association between the percentage of CD45\textsuperscript{+} immune cells and the proportion of luminal cells exhibiting a CD38\textsuperscript{lo} surface phenotype (Figures 3G and S3F).

\textbf{Reduced Androgen Signaling in CD38\textsuperscript{lo} Luminal Cells}

CD38\textsuperscript{lo} luminal cells express lower levels of Klk3, the gene for prostate-specific antigen (PSA) and other androgen-target genes (Klk2, Klk4, Msmb, Acpp, and Fkbp5) (Figure 3A), consistent with reduced androgen signaling observed in PIA lesions (De Marzo et al., 1999). Similar results were observed by microarray analysis. qPCR confirmed differences in Klk3 mRNA between the luminal subsets (Figure 4A). In contrast, levels of the luminal gene K8 were not significantly different (Figure 4A). Using CD38 expression was measured in 95\% (38/40) of inflamed glands, 88\% (35/40) of atrophic glands, and only 10\% (4/40) of normal glands from representative patient samples. Similar results were obtained for TNF, with strong expression in inflamed (38/40) and atrophic glands (33/40) with rare expression in normal glands (1/40).
immunohistochemistry, we confirmed diminished expression of androgen targets PSA, FKBP5, and MSMB in CD38lo luminal cells at the protein level (Figure 4B). Androgen receptor (AR) target NKX3-1 was also reduced in CD38lo luminal cells (Figure S4). We hypothesized that low androgen signaling in CD38lo luminal cells may be due to low levels of AR. While AR is expressed in CD38lo cells, protein levels are reduced compared to CD38hi luminal cells (Figures 1E and 4C).

**CD38lo Luminal Phenotype Is Associated with Disease Progression and Poor Outcome**

CD38 expression was previously reported to be reduced in a small cohort of prostate cancer specimens compared to benign prostate tissues (Kramer et al., 1995). We examined expression of CD38 in a tissue microarray containing tissue cores from 267 patients with prostate cancer (Gollapudi et al., 2013) (Table S2) and found the highest protein expression of CD38 in benign glands, with reduced expression in PIN and prostate cancer (Figures 5A and 5B; Table S3). The lowest expression of CD38 was found in the most advanced tumors based on Gleason grade (Figures 5A and 5B). Immunohistochemical staining was verified using two different anti-CD38 antibodies (Figure S5). While the average CD38 expression level was statistically significantly associated with time to biochemical recurrence, CD38 expression in cancer specimens was not statistically significant (Table S4).

Using the Memorial Sloan Kettering Cancer Center (MSKCC) dataset (Hieronymus et al., 2014; Taylor et al., 2010), we found that low CD38 mRNA in prostatectomy-derived prostate cancer samples is prognostic for biochemical recurrence and metastasis (Figures 5C and 5D) in a statistically significant manner (Table S5). Importantly, low CD38 mRNA status is statistically significantly associated with both biochemical recurrence and metastasis after correction for Stephenson nomogram score (Stephenson et al., 2005), which includes both clinical and pathological variables (Table S5). Low CD38 mRNA is also prognostic for biochemical recurrence in the Cancer Genome Atlas (TCGA) dataset (Network, 2015) (Figure 5E). Upon stratifying tumors based on genotype, we found that low CD38 mRNA expression was associated with SPINK1 outlier status, but not ETS-related gene (ERG) rearrangements, in the MSKCC cohort (Figure S6A).
These two markers can distinguish benign glands (CD38hi) from cancer (CD38lo PSCA-hi) (Figure 6B). We hypothesized that CD38lo PSCA-hi cancers may arise from the transformation of CD38lo PSCA-hi luminal cells.

### CD38lo Luminal Cells Express the Therapeutic Target PSCA

While CD38 expression is low in the most aggressive tumors, we reasoned that genes in the CD38lo luminal cell signature may be expressed in advanced disease and might serve as positive markers of this cell population. We used immunohistochemistry to investigate expression of prostate stem cell antigen (PSCA), a therapeutic target expressed in aggressive, metastatic, and castration-resistant prostate cancer (Gu et al., 2000). To determine whether the CD38lo luminal gene signature could provide value in predicting patient survival, we turned to a Swedish watchful waiting cohort containing outcome data for 281 men (Sboner et al., 2010). The mean of the scaled expression values of the CD38lo luminal genes was significantly (p = 0.037) associated with all-cause mortality after adjusting for Gleason sum, age, and cancer percentage (Table S6A). When we analyzed the patients most at risk for prostate cancer-related mortality, with a Gleason score greater than or equal to 7 and follow-up within 5 years, we found a statistically significant difference (p = 0.007) between patients whose expression values lie in the top third (CD38lo luminal-like) versus all others (Figure S6B; Table S6C). The statistical significance of the CD38lo signature within this restricted group reached p = 0.0007 after adjusting for Gleason sum, age, and cancer percentage (Table S6A). The CD38lo luminal gene signature is inversely correlated with the AR signature score (Hieronymus et al., 2006) in prostate tumor specimens in a statistically significant manner in multiple cohorts (Figure S6C). We confirmed that the effect of the CD38lo signature was independent of the androgen receptor signature (Hieronymus et al., 2006; Nelson et al., 2002) and a previously reported immune signature (Jin et al., 2014) (Tables S6D and S6E).

To determine whether the CD38lo luminal gene signature was associated with all-cause mortality after adjusting for Gleason sum, age, and cancer percentage (Table S6A). When we analyzed the patients most at risk for prostate cancer-related mortality, with a Gleason score greater than or equal to 7 and follow-up within 5 years, we found a statistically significant difference (p = 0.007) between patients whose expression values lie in the top third (CD38lo luminal-like) versus all others (Figure S6B; Table S6C). The statistical significance of the CD38lo signature within this restricted group reached p = 0.0007 after adjusting for Gleason sum, age, and cancer percentage (Table S6A). The CD38lo luminal gene signature is inversely correlated with the AR signature score (Hieronymus et al., 2006) in prostate tumor specimens in a statistically significant manner in multiple cohorts (Figure S6C). We confirmed that the effect of the CD38lo signature was independent of the AR signature (Hieronymus et al., 2006; Nelson et al., 2002) and a previously reported immune signature (Jin et al., 2014) (Tables S6D and S6E).

CD38lo Luminal Cells Can Regenerate Glands and Initiate Human Prostate Cancer

To determine the functional capacity of CD38lo luminal cells in tissue-regeneration and disease-initiation, we turned to an in vivo regeneration assay where human prostate epithelial cells are combined with urogenital sinus mesenchyme cells (UGSM) in Matrigel and transplanted subcutaneously into immune-deficient mice (Goldstein et al., 2010, 2011). To track human epithelial cells, we introduced genes for red and green fluorescent proteins into CD38lo luminal cells prior to in vivo transplantation (Figures 7A and S7A). Due to low cell numbers insufficient for direct in vivo implantation, we utilized a recently published approach to expand isolated cells in organoid culture for 1–2 weeks prior to transplantation (Park et al., 2016). An average of 200 lentiviral-transduced organoids derived from CD38lo luminal cells were combined with UGSM and implanted into NOD-SCID-IL2Rnull mice. 8 weeks post-transplantation, we identified prostatic glands containing both luminal cells expressing K8 and AR and basal cells expressing K5 and p63 (Figure 7B).

Lentiviral transduced human epithelial structures in regenerated tissues could be identified based on fluorescent signal, whereas control grafts without human cells lacked any epithelial structures or fluorescence (Figure S7C).

Oncogenes previously shown to transform primary human prostate (Goldstein et al., 2010; Stoyanova et al., 2013) (Myc, myristoylated AKT, and AR) were introduced into double-sorted CD38lo luminal cells via lentiviral delivery prior to in vitro expansion and in vivo transplantation. We identified features of human prostate adenocarcinoma, including expression of the luminal markers K8, PSA, and AR and an absence of the basal markers K5 and p63 in regenerated tumors derived from oncogene-expressing CD38lo luminal cells (Figure 7C). Regenerated tumors exhibited expression of oncogenes (Figure S7B). Importantly, tumors exhibited the PSCA-hi CD38lo luminal phenotype and a high frequency of cells expressed the proliferative marker Ki67 (>40% Ki67+) (Figure 7C). Results were confirmed using tissue from four independent patient samples. These findings indicate...
that CD38lo luminal cells can initiate human prostate cancer in vivo.

**DISCUSSION**

Chronic inflammation is associated with cancer initiation, progression, metastasis, and treatment resistance in a range of tumor types including prostate cancer (Das Roy et al., 2009; Gurel et al., 2014; Liu et al., 2013; Wang et al., 2015). In mouse models, several groups have established a tumor-promoting functional contribution of distinct immune cell types to prostate cancer, including B cells and myeloid-derived suppressor cells (Ammirante et al., 2010; García et al., 2014). However, little is known about the influence of inflammation on the function of human prostate epithelium prior to tumor formation. De Marzo and colleagues have proposed that inflammation may be an inciting event in prostate transformation and that PIA cells may serve as target cells for tumor initiation (De Marzo et al., 1999, 2003, 2010; Garcia et al., 2014). However, little is known about the influence of inflammation on the function of human prostate epithelium prior to tumor formation. De Marzo and colleagues have proposed that inflammation may be an inciting event in prostate transformation and that PIA cells may serve as target cells for tumor initiation (De Marzo et al., 1999, 2003, 2007). Our results demonstrate that PIA-like CD38lo luminal cells can initiate human prostate cancer.

Several groups have isolated human prostate luminal cells based on low expression of CD49f or high expression of CD26 for functional studies (Goldstein et al., 2010; Karthaus et al., 2014; Park et al., 2016; Stoyanova et al., 2013). We found that CD26 and CD38 identify an analogous population of prostate luminal cells (Figure S1C). While rare cells within the CD26+ or CD38hi luminal cell population exhibit organoid-forming activity, ~99% of cells in this subset do not exhibit progenitor features (Figures 2B–2D; Karthaus et al., 2014; Park et al., 2016). In contrast, CD38lo luminal cells are enriched for progenitor activity in 2D and 3D progenitor assays, as 5% of CD38lo luminal cells are capable of generating organoids (Figure 2D), similar to the rate of Lgr5-GFP-hi intestinal stem cells (Sato et al., 2009). Therefore, identifying the signaling pathways active in CD38lo luminal cells may yield mechanisms regulating luminal progenitor activity.

We found that CD38lo and CD38hi luminal cells have distinct transcriptional signatures. While androgen signaling is active in CD38hi luminal cells (Figure 4), CD38lo luminal cells exhibit elevated NF-κB signaling (Figure 3). Previous studies demonstrate that NF-κB activation can synergize with MYC overexpression or Pten heterozygosity to accelerate murine prostate cancer initiation and the NF-κB activation signature in human tumors can predict poor outcome (Birbach et al., 2011; Jin et al., 2014). These data suggest that NF-κB activity may predispose CD38lo luminal cells to tumor initiation. More work is necessary to determine whether strategies to reduce inflammation or small molecules that block epithelial NF-κB signaling can prevent prostate cancer initiation by targeting CD38lo luminal cell survival and progenitor activity.

CD38lo luminal cells express PSCA, which is being evaluated as a therapeutic target in clinical trials using monoclonal antibodies (Morris et al., 2012). BCL2 expression in CD38lo luminal cells may enhance their resistance to apoptosis (Raffo et al., 1995). Both BCL2 and PSCA are associated with castration resistance (Gu et al., 2000; Raffo et al., 1995), suggesting that CD38lo luminal cells may have a survival advantage under low-androgen conditions. Consistent with mouse models demonstrating that prostatic inflammation or epithelial NF-κB activation is associated with reduced androgen signaling and increased epithelial proliferation (Birbach et al., 2011; Khalili et al., 2010), CD38lo luminal cells express low levels of PSA and other androgen targets. These data suggest that CD38lo luminal-like cancer cells may contribute to castration-resistant prostate cancer.

Distinguishing indolent from aggressive prostate cancer remains a critical goal of the field. We found that low expression of CD38 mRNA in prostatectomy specimens is prognostic for biochemical recurrence in two independent cohorts (Figures 5C–5E). These data suggest that aggressive tumors may arise in CD38lo luminal cells that retain low expression of CD38.

---

**Figure 5. Association of CD38lo Phenotype with Prostate Cancer Progression**

(A) Plot of composite CD38 staining score in tissues histologically classified as normal, prostate intraepithelial neoplasia (PIN), or prostate cancer (CA) with Gleason scores less than 7 or 7–10. Middle bar represents mean value. The overall effect of different levels of CD38 among the prostate regions was confirmed (p < 0.001).

(B) Representative immunohistochemical images of normal, PIN, Gleason 6, and Gleason 8 cancer stained for CD38, with high-power images below.

(C and D) Survival analysis from MSKCC cohort measuring biochemical recurrence (C) and metastasis (D) for tumors containing CD38 mRNA 1 SD below the mean compared to the remainder (non-CD38lo). Log rank (Mantel Cox) p = 0.001 (recurrence in C) and p = 0.002 (metastasis in D).

(E) Survival analysis from the TCGA cohort measuring biochemical recurrence comparing CD38 expression less than (CD38lo) or greater than (non-CD38hi) the mean Z score. Log rank (Mantel Cox) p = 0.001.
Alternatively, the activation of a CD38lo luminal-like signature during tumorigenesis may promote an aggressive phenotype, regardless of the cell of origin. Several studies have looked at the cellular origins of cancer to distinguish indolent from aggressive prostate cancer with different results using distinct mouse models (Choi et al., 2012; Lu et al., 2013; Wang et al., 2009, 2013, 2014). In human prostate models, basal cells have been shown to generate aggressive, highly proliferative tumors, while luminal cells can initiate only indolent tumors (Goldstein et al., 2010; Park et al., 2016; Stoyanova et al., 2013). In this study, we demonstrate that CD38hi luminal cells can generate highly proliferative prostate cancer (>40% Ki67+). Taken together, we hypothesize that one target cell (basal) is predisposed to the initiation of aggressive cancer under normal conditions. In the context of chronic inflammation, a second target cell (CD38lo luminal) is predisposed to initiate aggressive cancer, perhaps due to elevated NF-κB signaling.

CD38lo luminal cells may arise from basal to luminal differentiation, as has been demonstrated using lineage tracing in mouse models of inflammation (Kwon et al., 2014, 2016). Alternatively, inflammation may alter the differentiation of luminal cells by enhancing NF-κB signaling and reducing androgen signaling. Future studies will determine whether exposure to inflammatory cytokines can reprogram CD38hi luminal cells into a progenitor-enriched CD38lo luminal-like cell capable of initiating aggressive prostate cancer. Interestingly, CD38lo luminal cells express cytokines and chemokines known to recruit pro-inflammatory cells and promote tumorigenesis in other tissues like Ccl2 (Qian et al., 2011) and Cxcl11/2 (Jablonska et al., 2014), indicating that CD38lo luminal cells may influence their microenvironment to promote inflammation and maintain proliferative cues.

Our findings are consistent with previous reports of low CD38 expression in prostate cancer (Kramer et al., 1995; Pascal et al., 2009). While rare deletions and mutations of CD38 can be identified in metastatic castration-resistant prostate cancer (Grasso et al., 2012; Robinson et al., 2015), transcriptional repression of CD38 is the likely mechanism causing low expression in the vast majority of prostate tumors. CD38 is an ectoenzyme that consumes the cofactor nicotinamide adenine dinucleotide (NAD) (Howard et al., 1993), suggesting that loss of CD38 may serve to increase pools of NAD required for cellular metabolism in prostate cancer. Further study of the functional role of CD38 in tumorigenesis and the cellular mechanisms driving CD38lo luminal cells may yield new predictive markers and therapeutic targets for aggressive disease.

**EXPERIMENTAL PROCEDURES**

**qPCR, RNA Sequencing, Bioinformatics, and Microarray**

RNA was extracted from cell pellets using the RNeasy mini Kit (QIAGEN/SA Biosciences), qPCR was carried out as previously described (Goldstein et al., 2010) using commercial primers to Gapdh, Keratin 8, and Kit3 (QIAGEN/SA Biosciences). RNA-seq libraries were prepared with the Ovation RNA-Seq System V2 (Nugen). Double-stranded cDNA was generated with a mixture of random and poly(T) priming, followed by fragmentation, generation of blunt ends by end repair, A-tailing, ligation of adaptors (different adaptors for multiplexing samples), PCR amplification, and sequencing (pair read 100 run) on Illumina HiSeq 2500. Illumina SAV was used for data quality check, and illumina CASAVA 1.8.2 was used for de-multiplexing. Reads were mapped to the most recent UCSC transcript set with Bowtie2 version 2.1.0. RSEM v1.2.15 was used to estimate level of gene expression. Gene expression was normalized by TPM (transcript per million) or RPKM (reads per kilobase per million mapped reads). DeSeq was used to identify differentially expressed genes. FASTQ files were not available at the time of publication. For that reason, the full RPKM values are provided in Table S1. Upstream regulator analysis was performed using QIAGEN’s Ingenuity Pathway Analysis (http://www.ingenuity.com). For microarray analysis, total RNA was isolated from sorted cells with RNeasy Micro Kit and amplified with NuGen Pico kit according to standard manufacturer protocols. Biotinylated cDNA were prepared from total RNA using the standard Affymetrix protocol and hybridized to the Affymetrix Human Genome U133 Plus 2.0 Chip. Chips were scanned using an Affymetrix GeneChip Scanner 7G and data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. Data are available at the GEO repository under accession number GEO: GSE89050.

**Primary Cell Preparation and Cell Separation**

Human prostate tissue samples were provided in a de-identified manner deemed by the institutional review board to not qualify as human subjects. Tissue was provided by the UCLA Translational Pathology Core Laboratory, and benign specimens were processed as described in detail previously (Goldstein et al., 2011). For antibody staining of primary benign dissociated cells, see Supplemental Information. Intracellular flow cytometry has been described previously (Goldstein et al., 2010). Antibodies are listed in Supplemental Information.
membranes probed with antibodies (see Supplemental Information). Primary rabbit, mouse, or goat antibodies were detected with horseradish peroxidase (HRP)-conjugated secondary antibodies (Pierce).

**Tissue Microarray and Scoring**

The tissue microarray was constructed from 332 men who underwent radical prostatectomy surgery at the West Los Angeles Veteran’s Administration Hospital from 1991 to 2003 and has been described previously (Gollapudi et al., 2013). At least three cores of each histological type are included per patient. Follow-up patient information for up to 120 months was used for analysis. Biochemical recurrence refers to PSA values greater than 0.2, two readings at 0.2, or additional treatment for high post-operative PSA. 4-μm sections were stained for CD38 and scanned using the Aperio scanner, and staining was evaluated in a blinded fashion by the pathologists (B.N. and J.H.). Scoring was based on the percentage of tumor cell expression (1%–100%), creating a composite score from 0 to 300. For statistical methods, see Supplemental Information.

**Cell Culture**

For the in vitro organoid-forming assay, double-sorted FACs-isolated cell populations were plated in a 96-well plate (Corning Incorporated) at a cell density of one cell per well, and those wells with a single cell were visually confirmed and marked for continued analysis. Prostate organoid growth conditions were based on established protocols (Karthauser et al., 2014). Primary single-cell organoids were dissociated in 1 mg/mL Dispase (Gibco) at 37°C for 1 hr and then treated with 0.05% Trypsin-EDTA (Life Technologies) in order to passage. For the colony assay, primary cells were plated on Matrigel-coated six-well dishes as described previously (Lukacs et al., 2010) and grown in PrEGM media. Colonies containing more than two cells were quantified after 10–14 days. For the sphere assay, cells were resuspended in a PrEGM/Matri- gel mixture and plated around the edges of the well in a 12-well dish as described previously (Lukacs et al., 2010). Spheres were quantified after 10–14 days. For inhibition of NF-κB, ACHP (4547, Tocris) was added to organoid media at a final concentration of 5 μM every 3 days.

**In Vivo Regeneration and Transformation and Animal Care**

In vivo tissue-regeneration and transformation methods have been described in detail (Goldstein et al., 2011). Transduced cells were expanded in organoid culture (Karthauser et al., 2014) prior to transplantation as described previously (Park et al., 2016). All human tissues were transplanted subcutaneously into NOD-SCID-IL2Rγcnull mice. Animals have been purchased from the Jackson Laboratory and are now housed and bred under the care of the Division of Laboratory Animal Medicine at the University of California, Los Angeles, using protocols approved by the Animal Research Committee. Lentiviral vectors were previously described (Goldstein et al., 2010; Stoyanova et al., 2013).

**ACCESSION NUMBERS**

The accession number for the data reported in this paper is GEO: GSE89050.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Supplemental Experimental Procedures, seven figures, and six tables and can be found with this article online at http://dx.doi.org/10.1016/j.celrep.2016.11.010.

**AUTHOR CONTRIBUTIONS**

ACKNOWLEDGMENTS

This work was supported by Department of Defense Idea Development Award W81XWH-13-1-0470 (A.S.G. and S.H.), a Prostate Cancer Foundation Young Investigator Award (A.S.G. and T.S.), the Broad Stem Cell Research Center (A.S.G. and J.H.), an AACR/PCF/Stand Up 2 Cancer West Coast Dream Team Award (O.N.W., J.H., M.R., and A.S.G.), a National Institute of Health/National Cancer Institute grant (R01CA184397; T.S.), and the Howard Hughes Medical Institute (O.N.W.). M.R. and funding for TMA creation were supported by the Howard Hughes Medical Institute (O.N.W.), M.R. and funding for TMA creation were supported by the Howard Hughes Medical Institute (O.N.W.).

REFERENCES


epithelial hyperplasia originated from basal cells. Stem Cell Res. (Amst.) 16, 682–691.